|
Market Cap (19-May) $8,702,824,448 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (5-May) 16,072,273 (4.76%) (53rd) |
|
52w High $31.97 |
52w Low $14.42 |
P/E 59.52 |
EPS 0.15 |
TLX released this announcement to the ASX on 12 April 2022, 9:28. The announcement is marked as price sensitive, and is 3 page(s) in length and 245.53kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 2.959% short sold according to ASIC data. It was ranked the 72nd most shorted stock on the ASX. It is now ranked as the 53rd most shorted stock on the ASX with 4.757% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| ProstACT TARGET Phase II Study Ethics Approval | 12 April 2022, 9:28 |
| Telix Enters Licence Agreement with Lilly for Olaratumab | 11 April 2022, 8:16 |
| Notification regarding unquoted securities - TLX | 8 April 2022, 8:20 |
| Telix, GMS & Monash Awarded $23 million Federal Funding | 4 April 2022, 10:00 |
You must be logged in to post a reply.
Telix Pharmaceuticals 